Value through Innovation27 July 2016

Policy On Transparency and Publication Of Clinical Study Data

Registration of Clinical Studies, Disclosure of Results in Publications and Results Databases and Access to Study Data and Documents

The free exchange of scientific information is the basis for innovation in medicine, especially the exchange of scientific results from human, interventional, and non-interventional clinical studies . As a research-driven pharmaceutical company, Boehringer Ingelheim supports this principle by seeking publication of the scientific results from all our studies in peer reviewed journals and at scientific meetings, regardless of study outcome.

Boehringer Ingelheim publicly registers all sponsored clinical studies and discloses the results. Furthermore, to benefit patients, public health, and to foster scientific discovery, Boehringer Ingelheim is committed to responsible sharing of clinical study reports (CSRs), related clinical documents, and patient-level clinical study data after drug approval or after termination of the drug development program.

These transparency commitments apply to studies initiated after January 1st, 1998.

Read the full version of Boehringer Ingelheim’s Transparency Policy

Office of Data Protection and Freedom of Information of the State of Rhineland-Palatinate: Statement on the anonymisation of individual subject data

Office of Data Protection and Freedom of Information of the State of Rhineland-Palatinate: Statement on the Anonymisation Report (EMA Policy 0070) for Praxbind